| Income Statement | 2025-09-30 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | 316 | 326 | ||
| Cost of revenues | 201 | 126 | ||
| Gross profit | 115 | 200 | ||
| Research and development expenses | 3,961 | 3,392 | ||
| Less participation by the national institute of allergy and infectious diseases, or niaid, the israeli innovation authority, or iia, and horizon europe | 30 | 503 | ||
| Research and development expenses, net | 3,931 | 2,889 | ||
| General and administrative expenses | 2,534 | 2,509 | ||
| Operating loss | -6,350 | -5,198 | ||
| Other financial income (expenses), net | 439 | -621 | ||
| Interest expenses | 229 | 217 | ||
| Total financial income (expenses), net | 210 | -838 | ||
| Loss before taxes | -6,140 | - | ||
| Tax benefit | -8 | - | ||
| Net loss | -6,132 | -6,036 | ||
| Net loss attributed to non-controlling interest | -282 | -154 | ||
| Net loss attributed to shareholders | -5,850 | -5,882 | ||
| Basic net loss per share (in dollars per share) | -0.65 | -1.08 | ||
| Diluted net loss per share (in dollars per share) | -0.65 | -1.08 | ||
| Weighted average number of shares used in computing basic net loss per share (in shares) | 8,995,635 | 5,459,236 | ||
| Weighted average number of shares used in computing diluted net loss per share (in shares) | 8,995,635 | 5,459,236 | ||
Pluri Inc. (PLUR)
Pluri Inc. (PLUR)